NDC 0069-0724-37 - Exubera
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0069-0724
- Requested NDC
- 0069-0724-37
- Package NDCs from labels
- 0069-0724-37
- Manufacturer
- Pfizer Inc.
- Effective date
- 2008-04-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| EXUBERA ® (insulin human [rDNA origin]) Inhalation Powder EXUBERA ® Inhaler | Pfizer Inc. | 2008-04-08 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0069-0724-37 | Exubera | 90 in 1 PACKAGE | AEROSOL, POWDER | 90 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| insulin human | ACTIVE INGREDIENT | 1Y17CTI5SR | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 | |
| insulin human | ACTIVE MOIETY | 1Y17CTI5SR | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 | |
| glycine | INACTIVE INGREDIENT | TE7660XO1C | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 | |
| sodium citrate | INACTIVE INGREDIENT | 1Q73Q2JULR | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | EXUBERA (INSULIN HUMAN) EXUBERA (INSULIN HUMAN) AEROSOL, POWDER [PFIZER INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | Mannitol |
| Mannitol | MANNITOL | ProPharma Distribution | 430669d7-9ad1-9a04-e063-6394a90ababb | 2025-11-07 | Warnings, Adverse reactions | Mannitol |
| Mannitol | MANNITOL | ICU Medical Inc. | ba7bf864-8a4d-4262-8fd1-00174fa2f9d1 | 2025-10-24 | Warnings, Adverse reactions | Mannitol |
| Glycine | GLYCINE | ICU Medical Inc. | c10a4657-cf64-4a71-a247-363dd58993bc | 2025-10-21 | Warnings, Adverse reactions | Glycine |
| Mannitol | MANNITOL | Henry Schein, Inc. | e2444db1-9dfe-451f-a33c-9b00786464d2 | 2025-05-20 | Warnings, Adverse reactions | Mannitol |
| MANNITOL | MANNITOL | HF Acquisition Co LLC, DBA HealthFirst | 999ce711-2d5b-0d7d-e053-2995a90a2689 | 2024-01-27 | Warnings, Adverse reactions | MANNITOL |
| Mannitol | MANNITOL | B. Braun Medical Inc. | d12cc802-b538-4065-a264-f474ff3b3043 | 2023-08-15 | Warnings, Adverse reactions | Mannitol |
| Mannitol | MANNITOL | Fresenius Kabi USA, LLC | c395e13d-6ea1-4104-8b37-669cfb982f04 | 2023-03-16 | Warnings, Adverse reactions | Mannitol |
| Glycine | GLYCINE | B. Braun Medical Inc. | f4d83550-42de-44c7-b8d5-1d0debc6aec2 | 2021-04-01 | Warnings, Adverse reactions | Glycine |
| Glycine | GLYCINE | Baxter Healthcare Corporation | d4665408-04d8-4ad7-8589-708d4defb869 | 2018-01-02 | Warnings, Adverse reactions | Glycine |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.